IP Library › Granted Patent US 12,337,023
Granted Patent B2
US 12,337,023 · App. 17/846,686 · Granted Jun 24, 2025

Methods and compositions for the prevention and treatment of disease

Inventor: D. Travis Wilson (Newton, MA)
Assignee: STEALTH BIOTHERAPEUTICS INC.
A61K38/07A61K31/165A61K31/192A61K31/727A61K31/737A61K38/06A61K38/13A61K38/1875A61K45/06A61P7/06A61P9/12A61P13/12A61P27/02A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,337,023
App. No.
17/846,686
Granted
Jun 24, 2025
Kind
B2
Abstract

The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.

Claims (12)

1. A method for reducing the risk of Alport Syndrome symptoms in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the subject harbors a mutation in one or more of COL4A3, COL4A4, and COL4A5.

3. The method of claim 1 , wherein the peptide is administered daily for 6 weeks or more.

4. The method of claim 1 , wherein the peptide is administered daily for 12 weeks or more.

5. The method of claim 1 , wherein the subject is human.

6. The method of claim 1 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intraperitoneally, intradermally, intraocularly, iontophoretically, transmucosally, or intramuscularly.

7. The method of claim 1 , further comprising separately, sequentially or simultaneously administering one or more additional therapeutic agents to the subject.

8. The method of claim 7 , wherein the one or more additional therapeutic agents are selected from the group consisting of: angiotensin II converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), HMG-COA reductase inhibitors, aldosterone inhibitors, calcineurin inhibitors, endothelin receptor antagonists, sulodexide, vasopeptidase inhibitors, anti-transforming growth factor-β1 antibodies, chemokine receptor 1 blockers, bone morphogenetic protein-7, PPARγ agonists, and matrix metalloprotease inhibitors (MMPIs).

9. The method of claim 1 , wherein the pharmaceutically acceptable salt comprises acetate, tartrate or trifluoroacetate salt.

10. The method of claim 1 , wherein peptide treatment results in elevated Mfn1 expression and/or function compared to an untreated Alport Syndrome subject.

11. The method of claim 8 , wherein the calcineurin inhibitor is cyclosporine A or tacrolimus; or wherein the endothelin receptor antagonist is sitaxentan, ambrisentan, atrasentan, BQ-123, zibotentan, bosentan, macitentan, tezosentan, BQ-788, or A192621; or wherein the vasopeptidase inhibitor is AVE7688; or wherein the PPARγ agonist is rosiglitazone, pioglitazone, MRL24, Fmoc- L -Leu, SR1664, SR1824, GW0072, MCC555, CLX-0921, PAT5A, L -764406, nTZDpa, CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid), ragaglitazar, O-arylmandelic acids, or a non-steroidal anti-inflammatory drug (NSAID); or wherein the MMPI is BAY-12-9566.

12. The method of claim 8 , wherein the additional therapeutic agent is aliskiren or sulodexide.

Assignments (4)
CHANGE OF ADDRESS Recorded May 14, 2025
From: STEALTH BIOTHERAPEUTICS INC.
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 071279/0966 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: WILSON, D. TRAVIS
To: STEALTH PEPTIDES INTERNATIONAL, INC.
Reel/Frame 061321/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: STEALTH BIOTHERAPEUTICS CORP
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 061612/0290 →
CHANGE OF NAME Recorded Oct 5, 2022
From: STEALTH PEPTIDES INTERNATIONAL, INC.
To: STEALTH BIOTHERAPEUTICS CORP
Reel/Frame 061612/0394 →
Continuity (4)
Continuation 16994799 · Aug 17, 2020
Division 15504944
Provisional Application 62040236 · Aug 21, 2014
Related Publication 20230043587A1 · Feb 9, 2023
References Cited (56)
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 5674534A · Zale et al. · 1997 [cited by applicant]
US 5716644A · Zale et al. · 1998 [cited by applicant]
US 8143219B2 · Szeto et al. · 2012 [cited by applicant]
US 11376304B2 · Wilson · 2022 [cited by examiner]
US 20090214488A1 · Kalluri · 2009 [cited by applicant]
US 20090221514A1 · Szeto et al. · 2009 [cited by applicant]
US 20120192298A1 · Weinstein et al. · 2012 [cited by applicant]
US 20130040901A1 · Szeto · 2013 [cited by examiner]
US 20130059784A1 · Wilson · 2013 [cited by applicant]
US 20130195837A1 · Borow et al. · 2013 [cited by applicant]
US 20130303436A1 · Wilson · 2013 [cited by applicant]
US 20140100263A1 · Duffield et al. · 2014 [cited by applicant]
WO WO9640073A2 · 1996 [cited by applicant]
WO WO9915154A1 · 1999 [cited by applicant]
WO WO0038651A1 · 2000 [cited by applicant]
WO WO2014210056A1 · 2014 [cited by applicant]
Anonymous “Collagen, Type IV, Alpha 3 (Goodpasture Antigen)” https://www.genecards.org/cgi-bin/carddisp.pl?gene=COL4A3 (Year: 2014). [cited by examiner]
Tarrida R “Drug Synergism: Its Detection and Applications” J. Pharmacology and Experimental Therapeutics 298:865-872. (Year: 2001). [cited by examiner]
Latif W “What is Alport Syndrome?” pennmedicine.org/for-patients-and-visitors/patient-information/conditions-treated-a-to-z/alport-syndrome (Year: 2019). [cited by examiner]
“COL4A3 gene” https://medlineplus.gov/genetics/gene/COL4a3/ (2020). [cited by applicant]
“COL4A4 gene” https://medlineplus.gov/genetics/gene/COL4a4/ (2020). [cited by applicant]
“COL4A5 gene” https://medlineplus.gov/genetics/gene/COL4a5/ (2020). [cited by applicant]
“Keratoconus” https://www.mayoclinic.org/diseases-conditions/keratoconus/diagnosis-treatmenUdrc-20351357 (2021). [cited by applicant]
“Treatment and Management of Alport Syndrome” https://alportsyndromenews.com/treatment-management-alport-syndrome (2019). [cited by applicant]
Abreu-Velez et al., “Collagen IV in Normal Skin and in Pathological Processes,” North American Journal of Medical Sciences, Jan. 2012, vol. 4, No. 1, pp. 1-8. [cited by applicant]
Anonymous, Alport Syndrome, National Library of Medicine Genetics Home Reference, https://ghr.nlm.nih.gov.condition/alport-syndrome (Year: 2019). [cited by applicant]
Canadian Office Action on CA 2958585 dated Sep. 2, 2021 (4 pages). [cited by applicant]
Chonn, et al., “Recent Advances in Liposomal Drug-Delivery Systems,” Curr. Opin. Biotechnol., Dec. 1995, vol. 6, Issue 6, pp. 698-708. [cited by applicant]
Cosgrove et al., “Collagen COL4A3 knouckout: A mouse model for autosomal Alport syndrome,” Genes Dev. 10(23):2981-92 (1996). [cited by applicant]
Cousins et al., “The mitochondria-targeted peptide MTP-131 prevents hydroquinone-mediated persistent injury phenotype in cultured retinal pigment epithelium cells”, Investigative Ophthalmology & Visual Science, Jun. 201… [cited by applicant]
Database Biosis, Jun. 2015, Cousins et al., “The mitochondria-targeted Peptide MPT-131 prevents hydroquinone-mediated persistent injury phenotype in cultured retinal pigment epithelium cells,” vol. 56, No. 7, Jun. 2015,… [cited by applicant]
Eirin et al., “A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis,” Hypertension, 2012 vol. 60, No. 5, pp. 1242-1… [cited by applicant]
Examination Report on EP Patent Application No. 15833335.1 dated Jul. 1, 2019 (4 pages). [cited by applicant]
Extended EP Search Report on EP Patent Application No. 15833335.1 dated Mar. 12, 2018. [cited by applicant]
Extended European Search Report on EP Patent Application No. 21167284.5 dated Oct. 6, 2021 (23 pages). [cited by applicant]
Final Office Action on U.S. Appl. No. 16/994,799 dated Nov. 10, 2021 (13 pages). [cited by applicant]
First Office Action on CN Patent Application No. 201580056853.X dated Jan. 22, 2020 (with English translation) (15 pages). [cited by applicant]
Gregoriadis, “Engineering Liposomes for Drug Delivery: Progress and Problems,” Trends in Biotechnology, Dec. 1995, vol. 13, No. 12, pp. 527-537. [cited by applicant]
Gregory et al., “Alport Syndrome—Clinical Phenotypes, Incidence, and pathology,” Contrib Nephrol, 117: 1-28 (1996). [cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US2015/046130 mailed Nov. 27, 2015. [cited by applicant]
Lichtenberg, et al., “Liposomes: Preparation, Characterization, and Preservation,” Methods Biochem. Anal., 1998, vol. 33, pp. 337-462. [cited by applicant]
Mizuguchi, et al., “Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth.” Cancer Lett., Feb. 26, 1996, vol. 100, Issue 1, pp. 63-69. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/504,944 dated Jul. 25, 2019. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 15/504,944 dated Apr. 14, 2020. [cited by applicant]
Notice of Allowance on U.S. Appl. No. 16/994,799 dated Feb. 28, 2022 (8 pages). [cited by applicant]
O'Brien, F. “Thin Basement Membrane Disease” Merck Manual. https://www.merckmanuals.com/professional/genitourinary-disorders/glomerular-disorders/thin-basement-membrane-disease (2020). [cited by applicant]
Reddy, “Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs,” Ann Pharmacother., Jul./Aug. 2000, vol. 34, pp. 915-923. [cited by applicant]
Restriction Requirement in U.S. Appl. No. 15/504,944 dated Dec. 28, 2018. [cited by applicant]
Rheault et al., “Mouse Model of X-Linked Alport Syndrome,” J Am Soc Nephrol. 15(6): 1466-74 (2004). [cited by applicant]
Shi et al., “Abstract 13175: A Mitochondrial-targeting Peptide (Bendavia) Regulates Matrix Metalloproteinase Expression and Preserves SERCA2a Pump Level I in the Noninfarcted Border Zone of Infarcted Hearts,” Circulatio… [cited by applicant]
Szeto et al., “Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury,” J Am Soc Nephrol, 2011, vol. 22, pp. 1041-1052. [cited by applicant]
Szeto, Hazel H., “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics”, British Journal of Pharmacology, 2014, vol. 171, pp. 2029-2050. [cited by applicant]
Weiner, Alan L., “Liposomes for Protein Delivery: Selecting Manufacture and Development Processes,” Immunomethods, Jun. 1994, vol. 4, No. 3, pp. 201-209. [cited by applicant]
Zhao, et al., “Transcellular Transport of a Highly Polar 3+ Net Charge Opioid Tetrapeptide,” Journal of Pharmacology and Experimental Therapeutics, 2003, vol. 304, No. 1, pp. 425-432. [cited by applicant]
Office Action on CA Patent Application No. 2958585 dated Aug. 25, 2022 (4 pages). [cited by applicant]